Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 12 h ago

NextCure, Inc.: Ikarian Capital, LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 17 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Ikarian Capital, LLC amended its Schedule 13G filing on NextCure, Inc., updating its beneficial ownership stake with the SEC under accession number 0001778253-26-000011. The filing signals a change in the investor's position in the clinical-stage biopharmaceutical company, though specific share counts and percentage figures were not disclosed in the filing summary. Schedule 13G amendments are typically watched for shifts in institutional ownership that can influence governance and sentiment around small-cap biotech names. Investors will look to the full filing for details on whether Ikarian increased, trimmed, or maintained its stake.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Ikarian Capital, LLC, NextCure, Inc.